Noteworthy Clinical Trials
- The ALCHEMIST Lung Cancer Trials
A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations.
- Lung-MAP: Master Protocol for Squamous Cell Lung Cancer
A collection of material about the Lung Cancer Master Protocol, or Lung-MAP, study that will examine treatment outcomes for patients with squamous cell lung cancer assigned to different study drug combinations based on the results of genomic profiling of their tumors.
- The ALTTO Breast Cancer Trial
(Updated: 06/01/2014) - A collection of material about the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation, or ALTTO, study that will compare the targeted agents lapatinib and trastuzumab alone, in sequence, or in combination as adjuvant therapy for HER2-positive breast cancer.
- The TAILORx Breast Cancer Trial
(Posted: 05/23/2006, Reviewed: 10/22/2010) - A collection of material about the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which will examine whether a molecular test can assign women with early-stage breast cancer to the most appropriate and effective treatment.
Testing and Screening Trials
- National Lung Screening Trial (NLST)
(Updated: 06/29/2011) - A collection of material about the National Lung Screening Trial (NLST), a research study sponsored by the National Cancer Institute that used low-dose helical CT scans or chest X-ray to screen men and women at risk for lung cancer.
- Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
A large-scale clinical trial to determine whether certain cancer screening tests reduce deaths from prostate, lung, colorectal, and ovarian cancer. In addition, there are numerous epidemiologic and ancillary studies going on that will answer other crucial questions about these cancers and these screening tests.